NOAH:NYSENoah Holdings Limited Analysis
Data as of 2026-05-19 - not real-time
$10.20
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Noah Holdings trades at a trailing P/E of 8.7, well below the asset‑management industry average of 16.7, and offers a 5.6% dividend yield with a payout ratio just above 50%, suggesting attractive income potential. Strong balance‑sheet metrics—$5.0 bn in cash versus $0.1 bn of debt—and solid operating margins (gross 53%, operating 35%) provide a cushion for continued dividend payments and modest growth. However, technical signals are mixed: the 20‑day SMA (10.52) sits just below the current price (10.2), the MACD is bearish, RSI hovers around 41, and the stock is testing a support near $10.02 while facing resistance around $11.05, indicating short‑term downside pressure. Market sentiment is extremely positive (Fear & Greed index 89) and the DCF‑derived fair value suggests ~32% upside, yet volatility remains high at ~27% and beta near 1, underscoring price swings. Overall, the company appears fundamentally undervalued with a sustainable dividend, but investors should watch technical weakness and broader macro‑risk in the Chinese wealth‑management space.
The recent shareholder communication and the proposal to distribute 100% of 2025 earnings as a dividend reinforce management’s confidence in cash generation. Coupled with a dual‑primary listing and insider ownership, these factors support a longer‑term bullish thesis, provided the firm can successfully transition to a recurring‑revenue model and navigate regulatory headwinds.
The recent shareholder communication and the proposal to distribute 100% of 2025 earnings as a dividend reinforce management’s confidence in cash generation. Coupled with a dual‑primary listing and insider ownership, these factors support a longer‑term bullish thesis, provided the firm can successfully transition to a recurring‑revenue model and navigate regulatory headwinds.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Bearish MACD and RSI near neutral suggest limited upside in the near term
- Price is near the identified support level of $10.02
- High dividend yield provides cushion while waiting for technical recovery
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Undervaluation relative to industry P/E and DCF upside of ~32%
- Strong cash position and low leverage support earnings growth
- Sustainable dividend with payout ratio ~52% enhances total return
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- Strategic shift to asset‑management‑driven recurring revenue improves margin stability
- Insider ownership aligns management interests with shareholders
- Long‑term demographic trends in China’s high‑net‑worth segment offer growth tailwinds
Key Metrics & Analysis
Financial Health
Revenue Growth12.50%
Profit Margin21.41%
P/E Ratio8.7
ROE5.57%
ROA4.13%
Debt/Equity1.03
P/B Ratio0.5
Op. Cash Flow$976.6M
Free Cash Flow$625.9M
Industry P/E16.7
Technical Analysis
TrendBearish
RSI40.9
Support$10.02
Resistance$11.05
MA 20$10.52
MA 50$10.59
MA 200$11.16
MACDBearish
VolumeStable
Fear & Greed Index89.27
Valuation
Fair Value$283.95
Target Price$13.46
Upside/Downside32.01%
GradeUndervalued
TypeValue
Dividend Yield5.63%
Risk Assessment
Beta1.04
Volatility26.96%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.